

“What’s New” Medical Pharmaceutical Policy June 2019 Updates

There were no new Medical Benefit Drug Policy changes or additions for the month of June

The following policies were reviewed with no changes:

- MBP 22.0 Xolair (omalizumab)
- MBP 75.0 Stelara (ustekinumab)
- MBP 89.0 Xgeva (denosumab)
- MBP 128.0 Blincyto (blinatumomab)
- MBP 141.0 Nucala (mepolizumab)
- MBP 145.0 Cinqair (reslizumab)
- MBP 156.0 Imfinzi (durvalumab)
- MBP 173.0 Fasentra (benralizumab)
- MBP 174.0 Luxturna (voretigene-neparvovec-rzyl)
- MBP 175.0 Mepsevii (vestronidase alfa-vjvk)
- MBP 177.0 Prevymis IV (letermovir)
- MBP 178.0 Zilretta (triamcinolone acetonide ER injection)